We spend billions on end-of-life healthcare that doesn’t do much good. So what if a patient could forego the standard treatment and get a cash rebate instead?
Season 5, Episode 19
On this week’s episode of Freakonomics Radio: We spend billions of dollars on end-of-life healthcare that often doesn’t do much good. So what if a patient could forego the standard treatment and get a cash rebate instead?
Also, the war on cigarettes has been fairly successful in some places. In the U.S., the smoking rate has fallen by more than half. But a billion humans still smoke, so what comes next?
The gist: we spend billions on end-of-life healthcare that doesn’t do much good. So what if a patient could forego the standard treatment and get a cash rebate instead?
In a wide-ranging conversation with Ezekiel Emanuel, the policymaking physician and medical gadfly, we discuss the massive effects of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro. We also talk about the state of cancer care, mysteries in the gut microbiome, flaws in the U.S. healthcare system — and what a second Trump term means for healthcare policy.
In a wide-ranging conversation with Ezekiel Emanuel, the policymaking physician and medical gadfly, we discuss the massive effects of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro. We also talk about the state of cancer care, mysteries in the gut microbiome, flaws in the U.S. healthcare system — and what a second Trump term means for healthcare policy.
You want to listen to Freakonomics Radio? That’s great! Most people use a podcast app on their smartphone. It’s free (with the purchase of a phone, of course). Looking for more guidance? We’ve got you covered.
Stay up-to-date on all our shows. We promise no spam.
